How does tirzepatide compare to semaglutide for weight reduction in adults without diabetes?

Tirzepatide and semaglutide are both injectable medications approved for weight management. Tirzepatide targets two gut hormones (GIP and GLP-1), while semaglutide targets only GLP-1. In adults without diabetes, tirzepatide consistently produces greater weight reduction than semaglutide, though both are effective.

What the research says

A Bayesian network meta-analysis of six randomized trials found that tirzepatide 10 mg and 15 mg led to significantly greater percentage weight loss than semaglutide 2.4 mg in adults without diabetes: about 4.85% and 6.26% more weight loss, respectively ¹. A large cohort study using electronic health records also showed that tirzepatide users were more likely to achieve 5%, 10%, and 15% weight loss compared to semaglutide users ⁹. A systematic review and network meta-analysis on body composition reported that tirzepatide 15 mg and semaglutide 2.4 mg were the most effective for reducing total weight and fat mass, but tirzepatide was among the least effective in preserving lean mass ¹⁰. An indirect treatment comparison in people with type 2 diabetes similarly found tirzepatide superior to semaglutide for weight loss ¹¹, though that study focused on a different population. Overall, the evidence consistently favors tirzepatide over semaglutide for weight reduction in adults without diabetes.

What to ask your doctor

• How do tirzepatide and semaglutide differ in their mechanisms and expected weight loss results?
• What are the potential side effects of each medication, especially gastrointestinal issues?
• Which medication might be better for me based on my health profile and weight loss goals?
• How does each medication affect body composition, including muscle mass?
• What is the cost and insurance coverage for tirzepatide versus semaglutide?